Glutathione kinetics in normal man and in patients with liver cirrhosis. 1997

G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
Dipartimento di Medicina Interna, Università di Bologna, Italy.

OBJECTIVE The dynamics of glutathione in plasma has always been studied by bolus injections. Data are available suggesting that the low plasma levels of cirrhosis are due to decreased production in glutathione-producing tissues, mainly the liver. We aimed to measure the kinetics of glutathione during controlled steady-state conditions, and to determine the reasons for its reduced plasma levels in advanced cirrhosis. METHODS The plasma clearance of glutathione was measured in six control subjects and in ten patients with cirrhosis during a 2-step infusion study, producing steady-state levels approximately 5 and 10 times basal values. The plasma disappearance curve after infusion stop was used to determine the apparent volume of distribution and half-life of glutathione, and the estimated basal appearance rate. RESULTS The clearance of glutathione did not reject 1st-order kinetics, i.e., it was concentration-independent, and was nearly doubled in cirrhosis. The half-life of exogenous glutathione was not different, whereas the volume of distribution was larger in cirrhosis, in the same range as extracellular water. The endogenous basal appearance rate of glutathione was reduced by 50%, and correlated with liver function, measured by routine and dynamic tests. CONCLUSIONS The data confirm that the primary defect responsible for reduced glutathione in liver disease is a reduced production, possibly related to hepatocyte dysfunction and a block along the pathway of methionine metabolism.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008715 Methionine A sulfur-containing essential L-amino acid that is important in many body functions. L-Methionine,Liquimeth,Methionine, L-Isomer,Pedameth,L-Isomer Methionine,Methionine, L Isomer
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005260 Female Females
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
January 1966, Scandinavian journal of clinical and laboratory investigation. Supplementum,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
December 1978, Gut,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
December 2009, Southern medical journal,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
June 1989, Clinical pharmacology and therapeutics,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
July 1996, Journal of hepatology,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
September 1979, Quaderni Sclavo di diagnostica clinica e di laboratorio,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
January 1975, Digestion,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
January 2006, Acta biochimica Polonica,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
January 1977, Arzneimittel-Forschung,
G Bianchi, and E Bugianesi, and M Ronchi, and A Fabbri, and M Zoli, and G Marchesini
January 1992, Chemotherapy,
Copied contents to your clipboard!